Cargando…
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Intravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mou...
Autores principales: | Zhu, Annie, Rajendram, Phavalan, Tseng, Eric, Coutts, Shelagh B., Yu, Amy Y. X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487449/ https://www.ncbi.nlm.nih.gov/pubmed/36186106 http://dx.doi.org/10.1002/rth2.12795 |
Ejemplares similares
-
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
por: Yang, Nan, et al.
Publicado: (2023) -
Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study
por: Dhar, Nikita, et al.
Publicado: (2022) -
Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke
por: Nguyen, Chi Phuong, et al.
Publicado: (2023) -
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review
por: Potla, Neha, et al.
Publicado: (2022) -
Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
por: Xu, Na, et al.
Publicado: (2018)